{"entity":{"id":"paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002","kind":"paper","name":"Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase 2 trial","aka":[],"tldr":"The combination of gemcitabine and docetaxel produced responses in more than half of patients with leiomyosarcoma, most of them uterine and many previously treated with doxorubicin, establishing a widely used second regimen for the disease.","summary":"Phase 2 study of 34 patients with unresectable leiomyosarcoma (29 uterine) treated with fixed-dose-rate gemcitabine followed by docetaxel every three weeks with growth factor support.\n\nObjective response was 53 percent including three complete responses, with responses in patients previously treated with doxorubicin; median time to progression was 5.6 months and myelosuppression was the main toxicity.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2002","url":"https://doi.org/10.1200/JCO.2002.11.050"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/12065559/"}],"tags":[],"related":[],"cancers":["leiomyosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["docetaxel","gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2002,"doi":"10.1200/JCO.2002.11.050","pmid":"12065559","authors":"Hensley ML, Maki R, Venkatraman E, et al.","paperType":"observational","findings":["Objective response 53 percent (18 of 34).","Responses in patients with prior doxorubicin exposure."],"whatItMeans":"Gemcitabine-docetaxel is a standard first- or second-line option for leiomyosarcoma, especially uterine, and remains in use alongside doxorubicin-based regimens.","caveats":["Single-arm study; randomised trials (GeDDiS) later found gemcitabine-docetaxel no better than doxorubicin first line."],"changedPractice":true,"participants":34},"route":"/key-papers/paper-hensley-gemcitabine-docetaxel-leiomyosarcoma-jco-2002/","neighbours":{"cancer":[{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}